Arthrosis is a common degenerative joint disease that damages joint cartilage and the underlying bone. Risk factors include sports injuries, obesity, joint misalignment, and aging. In Germany one in five people over 65 is affected by a degree of arthritis and in 72 % of cases can, without treatment, lead to progressive osteoarthritis and total joint replacement. Deep cartilage defects, or osteochondral lesions, affect the cartilage-bone interface. The current gold standard involves autologous cartilage-bone grafts, where cylindrical grafts are harvested from less stressed joint areas and implanted in defect sites. However, this approach is limited by the availability of donor material, varying cartilage thickness, and donor site morbidity. To address these issues, this project focuses on developing a biphasic, resorbable, porous bone-cartilage implant. The implant aims to replicate the biological and mechanical properties of cartilage and bone, including the calcified cartilage transition zone and fibrous cartilage structure, with an emphasis on biomimetic design. Porous cylindrical scaffolds are additively manufactured from a biocompatible and absorbable magnesium alloy to replicate bone structure. Various geometries are being explored and adapted to meet bone material requirements, with a focus on evaluating the degradation behaviour of the bone phase for biomimetic implant design.For cartilage replacement nanofiber nonwovens are combined with hydrogels and coated onto the bone phase. Electrospinning is used to produce nanofiber scaffolds that reinforce the mechanical properties of the hydrogel and are attached to the metal scaffolds. The use of hydrogel and nanofibers creates a biocompatible environment to replicate the cartilage structure and improve cell viability and differentiation, while providing the necessary mechanical support during the healing period.The implant’s mechanical integrity is assessed through compression and shear tests, while its biocompatibility, and cell- viability and adhesion are evaluated via ex vivo trials. This biphasic implant aims to reduce complications, follow-up surgeries, and healthcare costs.